NDS Updates

The following are the tentative meeting dates for the National Drug Scheduling Advisory Committee (NDSAC) in 2022.  https://www.napra.ca/meeting-schedule

The National Association of Pharmacy Regulatory Authorities (NAPRA) has received questions about the scheduling of mupirocin. Mupirocin is listed in Schedule I of the National Drug Schedules (NDS). The National Drug Scheduling Advisory

The National Association of Pharmacy Regulatory Authorities (NAPRA) has received questions about the scheduling of mometasone nasal spray. Mometasone furoate for the treatment of allergic rhinitis in a nasal spray

The interim recommendations made by the National Drug Scheduling Advisory Committee (NDSAC) on June 6-7, 2021 that: Non-live recombinant herpes zoster vaccine – be granted Schedule II status Bisacodyl, when

The proposed meeting of the National Drug Scheduling Advisory Committee (NDSAC) September 19-20, 2021 is cancelled. The next meeting of the Committee is scheduled for December 5-6, 2021. The deadline to

In July 2020, the National Drug Schedules (NDS) of the National Association of Pharmacy Regulatory Authorities (NAPRA) were amended to add the following listings: NAPRA has received a few questions

A meeting of the National Drug Scheduling Advisory Committee (NDSAC) was held on June 6-7, 2021 with the following interim recommendations made: Non-live recombinant herpes zoster vaccine – be granted

In accordance with its Policy on Natural Health Products (NHPs), the National Association of Pharmacy Regulatory Authorities (NAPRA) was to have removed all NHPs from the National Drug Schedules (NDS) on January

The next meeting of the National Drug Scheduling Advisory Committee (NDSAC) is scheduled for June 6 and 7, 2021. The primary purpose of the meeting is to consider the following matters:

The National Drug Scheduling Advisory Committee (NDSAC) is a committee of the National Association of Pharmacy Regulatory Authorities (NAPRA) which serves to advise NAPRA on matters relating to the National